Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer's disease risk in the general population: a Mendelian randomisation study

被引:47
|
作者
Zheng, Jie [1 ,2 ,3 ]
Xu, Min [1 ,2 ]
Walker, Venexia [3 ]
Yuan, Jinqiu [4 ,5 ,6 ,7 ]
Korologou-Linden, Roxanna [3 ]
Robinson, Jamie [3 ]
Huang, Peiyuan [3 ]
Burgess, Stephen [8 ,9 ]
Yeung, Shiu Lun Au [10 ]
Luo, Shan [10 ]
Holmes, Michael, V [3 ,11 ,12 ,13 ]
Smith, George Davey [3 ,14 ,15 ]
Ning, Guang [1 ,2 ]
Wang, Weiqing [1 ,2 ]
Gaunt, Tom R. [3 ,14 ,15 ]
Bi, Yufang [1 ,2 ]
机构
[1] Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai Inst Endocrine & Metab Dis, Dept Endocrine & Metab Dis,Sch Med, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Shanghai Natl Clin Res Ctr Metab Dis, Ruijin Hosp,Shanghai Key Lab Endocrine Tumor,Stat, Key Lab Endocrine & Metab Dis,Sch Med,Natl Hlth C, Shanghai, Peoples R China
[3] Univ Bristol, MRC, Integrat Epidemiol Unit IEU, Bristol Med Sch, Oakfield House, Bristol, Avon, England
[4] Sun Yat Sen Univ, Affiliated Hosp 7, Clin Res Ctr, Shenzhen, Guangdong, Peoples R China
[5] Sun Yat Sen Univ, Affiliated Hosp 7, Ctr Digest Dis, Shenzhen, Guangdong, Peoples R China
[6] Guangzhou Women & Children Med Ctr, Guangzhou, Guangdong, Peoples R China
[7] Chinese Univ Hong Kong, JC Sch Publ Hlth & Primary Care, Div Epidemiol, Hong Kong, Peoples R China
[8] Cambridge Inst Publ Hlth, Biostat Unit, MRC, Cambridge, England
[9] Univ Cambridge, Dept Publ Hlth & Primary Care, Cardiovasc Epidemiol Unit, Cambridge, England
[10] Univ Hong Kong, Li Ka Shing Fac Med, Sch Publ Hlth, Pokfulam, Hong Kong, Peoples R China
[11] Univ Oxford, Populat Hlth Res Unit, MRC, Oxford, England
[12] Univ Oxford, Nuffield Dept Populat Hlth, Clin Trial Serv Unit, Oxford, England
[13] Oxford Univ Hosp, Oxford Biomed Res Ctr, Natl Inst Hlth Res, Oxford, England
[14] Univ Hosp Bristol NHS Fdn Trust, NIHR Biomed Res Ctr, Bristol, Avon, England
[15] Univ Bristol, Bristol, Avon, England
基金
英国惠康基金; 中国国家自然科学基金; 英国医学研究理事会;
关键词
Alzheimer's disease; Brain expression; Cognitive function; Dementia; Mendelian randomisation; Metformin targets; Mitochondrial function; COGNITIVE DECLINE; INSTRUMENTS; DONEPEZIL; DEMENTIA; BIAS;
D O I
10.1007/s00125-022-05743-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims/hypothesis Metformin use has been associated with reduced incidence of dementia in diabetic individuals in observational studies. However, the causality between the two in the general population is unclear. This study uses Mendelian randomisation (MR) to investigate the causal effect of metformin targets on Alzheimer's disease and potential causal mechanisms in the brain linking the two. Methods Genetic proxies for the effects of metformin drug targets were identified as variants in the gene for the corresponding target that associated with HbA(1c) level (N=344,182) and expression level of the corresponding gene (N=31,684). The cognitive outcomes were derived from genome-wide association studies comprising 527,138 middle-aged Europeans, including 71,880 with Alzheimer's disease or Alzheimer's disease-by-proxy. MR estimates representing lifelong metformin use on Alzheimer's disease and cognitive function in the general population were generated. Effect of expression level of 22 metformin-related genes in brain cortex (N=6601 donors) on Alzheimer's disease was further estimated. Results Genetically proxied metformin use, equivalent to a 6.75 mmol/mol (1.09%) reduction on HbA1c, was associated with 4% lower odds of Alzheimer's disease (OR 0.96 [95% CI 0.95, 0.98], p=1.06x10-4) in non-diabetic individuals. One metformin target, mitochondrial complex 1 (MCI), showed a robust effect on Alzheimer's disease (OR 0.88, p=4.73x10-4) that was independent of AMP-activated protein kinase. MRof expression in brain cortex tissue showed that decreased MCI-related gene (NDUFA2) expression was associated with lower Alzheimer's disease risk (OR 0.95, p=4.64x10-4) and favourable cognitive function. Conclusions/interpretation Metformin use may cause reduced Alzheimer's disease risk in the general population. Mitochondrial function and the NDUFA2 gene are plausible mechanisms of action in dementia protection.
引用
收藏
页码:1664 / 1675
页数:12
相关论文
共 50 条
  • [1] Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer’s disease risk in the general population: a Mendelian randomisation study
    Jie Zheng
    Min Xu
    Venexia Walker
    Jinqiu Yuan
    Roxanna Korologou-Linden
    Jamie Robinson
    Peiyuan Huang
    Stephen Burgess
    Shiu Lun Au Yeung
    Shan Luo
    Michael V. Holmes
    George Davey Smith
    Guang Ning
    Weiqing Wang
    Tom R. Gaunt
    Yufang Bi
    Diabetologia, 2022, 65 : 1664 - 1675
  • [2] Genetically proxied lean mass and risk of Alzheimer's disease: mendelian randomisation study
    Daghlas, Iyas
    Nassan, Malik
    Gill, Dipender
    BMJ MEDICINE, 2023, 2 (01):
  • [3] Evaluating the impact of metformin targets on the risk of osteoarthritis: a mendelian randomization study
    Zhang, Y.
    Li, D.
    Zhu, Z.
    Chen, S.
    Lu, M.
    Cao, P.
    Chen, T.
    Li, S.
    Xue, S.
    Zhu, J.
    Ruan, G.
    Ding, C.
    OSTEOARTHRITIS AND CARTILAGE, 2022, 30 (11) : 1506 - 1514
  • [4] Association between dietary fat intake and the risk of Alzheimer's disease: Mendelian randomisation study
    Zhu, Yunqing
    Lan, Yongbing
    Lv, Jun
    Sun, Dianjianyi
    Li, Liming
    Zhang, Dai
    Yu, Canqing
    Yue, Weihua
    BRITISH JOURNAL OF PSYCHIATRY, 2025, 226 (01) : 24 - 30
  • [5] EVALUATING THE IMPACT OF METFORMIN TARGETS ON THE RISK OF RHEUMATOID ARTHRITIS: A MENDELIAN RANDOMIZATION STUDY
    Wang, Q.
    Gao, Y.
    Yang, T.
    Qiao, J.
    Zhang, S. X.
    Wang, C.
    Li, X.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1220 - 1221
  • [6] Efficacy of metformin targets on cardiometabolic health in the general population and non-diabetic individuals: a Mendelian randomization study
    Zheng, Jie
    Xu, Min
    Yang, Qian
    Hu, Chunyan
    Walker, Venezia
    Lu, Jieli
    Wang, Jiqiu
    Liu, Ruixin
    Xu, Yu
    Wang, Tiange
    Zhao, Zhiyun
    Yuan, Jinqiu
    Burgess, Stephen
    Yeung, Shiu Lun Au
    Luo, Shan
    Anderson, Emma L.
    V. Holmes, Michael
    Smith, George Davey
    Ning, Guang
    Wang, Weiqing
    Gaunt, Tom R.
    Bi, Yufang
    EBIOMEDICINE, 2023, 96
  • [7] Can metformin lower the risk of Alzheimer's in the general population?
    Burgess, Stephanie
    DIABETOLOGIE UND STOFFWECHSEL, 2023, 18 (01) : 22 - 22
  • [8] Unhealthy Behaviours and Risk of Parkinson's Disease: A Mendelian Randomisation Study
    Heilbron, Karl
    Jensen, Melanie P.
    Bandres-Ciga, Sara
    Fontanillas, Pierre
    Blauwendraat, Cornelis
    Nalls, Mike A.
    Singleton, Andrew B.
    Smith, George Davey
    Cannon, Paul
    Noyce, Alastair J.
    JOURNAL OF PARKINSONS DISEASE, 2021, 11 (04) : 1981 - 1993
  • [9] Systematic druggable genome-wide Mendelian randomisation identifies therapeutic targets for Alzheimer's disease
    Su, Wei-Ming
    Gu, Xiao-Jing
    Dou, Meng
    Duan, Qing-Qing
    Jiang, Zheng
    Yin, Kang-Fu
    Cai, Wei-Chen
    Cao, Bei
    Wang, Yi
    Chen, Yong-Ping
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2023, 94 (11): : 954 - 961
  • [10] Letter to the editor: Genetically determined IBD is associated with decreased risk of Alzheimer's disease: a Mendelian randomisation study
    Guo, Xingzhi
    Chong, Li
    Zhang, Xin
    Li, Rui
    GUT, 2022, 71 (08) : 1688 - 1689